

## Hull and East Riding Prescribing Committee Minutes – Confirmed

<b>Date / Time</b>	Wednesday 31 <sup>st</sup> January 2018
<b>Venue</b>	Board Room ,Health House, Willerby
<b>Chair</b>	Dr S Raise, GP Prescribing Lead, ER
<b>Notes / Action Points</b>	Mrs S Greene, Senior Pharmacy Technician – Formulary/Interface, HEY.
<b>Quorate: Yes / No</b>	Yes

Mr Kevin McCorry, Senior Pharmacist, ERY, NECS  
Mr Antonio Ramirez, Senior Principal Pharmacist- Interface HEY  
Prof A Morice, Professor of Respiratory Medicine  
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY  
Dr K Raghunath, GP Prescribing Lead, Hull CCG  
Mr S Gaines, Senior Principal Pharmacist, HEY  
Janet Clarke Chief Officer Local Pharmaceutical Committee ERHLPC  
Dr W Chong, Chief Pharmacist, HFT  
Phil Davis, Head Of Primary Care, Hull, CCG  
Mrs Jackie Stark, Principal Pharmacist Humber

<b>Apologies</b>	Tim Allison Dr Krishna Kasaraneni, Humberside LMC Medical Director Julie Moore, HFT, Non-Medical Prescribing Lead/Medicine Optimisation Lead Nurse
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2018.01.01	Apologies	As above.				
2018.01.02	Declarations of Interest	None.				
2018.01.03	Minutes of the previous meeting	Accepted as a true record.				
2018.01.04	Action Tracker	<p><b>Shared Care Framework Acetylcholinesterase Inh Dementia</b> – Feedback from LL. The pilot has been extended to the end of March.</p> <p><b>Paediatric Growth Hormone SCF</b> No update from Commissioners yet.</p> <p><b>Bisphosphonates as Supportive Therapy for Breast Cancer</b> –Approved at D&amp;T, agreed as a blue. Prof Lind is writing a guideline.</p> <p><b>Diabetes Formulary GLP-1 Agonists</b> No feedback received as yet.</p> <p><b>Guideline on Prescribing of Gonadorelin Analogues and Gonadotrophin Releasing Hormone Antagonists in the Treatment of Prostate Cancer</b> AR had received feedback from urologists that they agree with the SCF. Approval needed by March for patient's use but not seen by commissioners yet. If not approved by then, patients needing Degarelix could go use an IFR.</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>AR to re circulate document to Committee for comments.</p>	<p>Defer until May</p> <p>Defer until May</p> <p>Update in March</p> <p>Update in March</p> <p>Update in March</p>	<p>LL</p> <p>CB/DC</p> <p>Prof L/AR</p> <p>AR</p> <p>AR</p>	<p>05/18</p> <p>05/18</p> <p>03/18</p> <p>03/18</p> <p>03/18</p>

		<p><b>Oral Nutritional Supplements</b>  A discussion had taken place. As per nutrition flow chart, high risk patients are referred and seen by dieticians in the Community. However moderate risk patients discharged by HEY will not be referred. Without nutritional input on the IDS the reasons and duration of treatments for oral supplements for these patients are sometimes uncertain. It's agreed by this committee that once the supplements supplied by hospital run out, GPs will not re-prescribe them.  The flowchart needs to reflect this decision and will be published under guidelines on the HERPC webpage.</p> <p><b>Feedback From Commissioning Groups. Primary/Secondary care agreement.</b>  LMC document discussed. Summary of the New standard NHS contract from 2017. Humber FT and CHCP not included in circulation list. KK to do so.</p> <p><b>DMARD Prescribing Shared Care Agreement.</b>  Meeting have taken place today. Agreed to change the clinic letter from hospital to GP to include all blood results and continue to work as per each DMARDs SCF. Recommendations passed to LMC for comments</p> <p><b>Roflumilast for Treating Chronic Obstructive Pulmonary Disease</b> SCF to be written.</p> <p><b>Fluticasone Furoate and Vilanterol (Relvar Ellipta) COPD</b> Respiratory under review</p> <p><b>Guidelines for the Management of Erectile Dysfunction in Primary Care.</b> GH had sent information on devices, and this was cascaded to the Committee for information. <i>(We tend to go for the iMedicare Soma2 erect vacuum pumps. They have a good guarantee and follow up service)</i></p>	<p>Action Complete</p> <p>Action Complete</p> <p>Ongoing</p> <p>Pending SCF</p> <p>Pending reviewed pathway</p> <p>Action Compete</p>	<p>AR to feedback to nutrition group</p> <p></p> <p>Update in March</p> <p>Update in March</p> <p>Update in March</p>	<p></p> <p></p> <p>LMC/AR</p> <p>AR</p> <p>AR</p>	<p>01/18</p> <p>01/18</p> <p>03/18</p> <p>03/18</p> <p>03/18</p> <p>01/18</p>
--	--	--	---	---	---	---

	<p><b>Prescribing Framework for Isocarboxazid in the treatment of Depressive illness</b> Final amendments done and website updated.</p>	Action Complete		AR/SG	01/18
	<p><b>Guanfacine Shared Care Framework.</b> Paediatric cardiologist consulted and feedback that ECG's would not need to be routinely done to all patients before prescribing. Only high risk patients identified as per SPC. SCF agreed on these terms. For web</p>	Action Complete		AR/SG	01/18
	<p><b>Ivermectin</b> Had been agreed as blue on formulary. Included in the rosacea guideline. For web</p>	Action completed		AR/SG	01/18
	<p><b>Adult Renal Transplant GP Prescribing</b> Information on transfer of care amended on document. Pending repatriation to hospital. Documents to be sent to LMC for comments on SCF for new patients until repatriation happens.</p>	Ongoing		KK	01/18
	<p><b>Information Leaflet for Buprenorphine Patches</b> Logo and brands had been added. For Web</p>	Action Complete		SG	01/18
	<p><b>Prescribing for patients with heart failure with reduced ejection fraction</b> Amendments had been done and Web updated</p>	Action Complete		SG	01/18
	<p><b>“Unlicensed” and “off label” Medicines patient information leaflet.</b> Phrase removed. For web</p>	Action Complete		SG	03/18
	<p><b>Flash Glucose Monitoring Systems</b> Approved at D&amp;T as a Red drug</p>	Action completed			01/18
	<p><b>Guidance on Citalopram and Escitalopram.</b> Updated document, re-wording of title: <i>maximum doses and new contraindications</i> had been removed. Added to web.</p>	Action completed		SG	01/18

2018.01.05	Traffic Light Status	<p><b>HEY D&amp;T November/December</b>  Cladribine tablets – Red  Regorafenib (Stivarga) Caps 40mg – Red  Flamigel and Flaminial Hydro - Green  Tofacinitib (Xeljanz) – Red  Opicapone – Green  Imuderm – Green  Etelcalcetide Injection – Red  Eluxadoline Tablet – Blue  Pure Fructose (Hydrogen Breath Test) – Red  Trimbow MDI - Green  Baricitinib (Olumiant) - Red  Free Style Libre – Red</p> <p>Rheumatology at HEY want to use Tofacinitib as per NICE TA with the draft RA pathway before formal approval. The question wasn't raised properly by AR (usage before 90 days post NICE)</p>	Asked KM and agreed pending pathway			
2018.01.06	Feedback From Commissioning Groups	<p><b>Standard Operating Procedure for the administration of Red and Amber Drugs within Integrated Community Care Services</b> – This document was brought to the committee as CHCP Community nurses administer red drugs to patients in their homes.</p> <p><b>Primary/Secondary care agreement</b> - Noted</p> <p><b>Flash Glucose Monitory Systems</b> - Approved at D&amp;T as a Red drug</p>	<p>EB to amend system of communication by nurses to GP practices including practices nhs.net email address and add HERPC logo</p> <p>To be circulated to all parties, including CHCP and HFT</p> <p>Noted</p>	<p>Update and web</p> <p>KK</p> <p>update website</p>	<p>EB/GH/SG</p> <p>KK</p> <p>SG</p>	<p>01/03</p> <p>01/03</p> <p>01/03</p>

2018.01.07	Prescribing guidelines, shared care frameworks for approval	<p><b>Guideline for the Treatment of Rosacea</b> – Ivermectin agreed as blue by specialist advice on the formulary. Three months duration to be added to the first and second line agents on guideline.</p>	AR to re format, around treatment and duration.	HERPC logo and web	AR/SG	01/18
		<p><b>Guidance for use of Sodium Valproate and Valproic Acid in Females with child bearing potential.</b> Approved Contact details to be added for urgent referrals for ladies already pregnant and taking sodium valproate. To Include links to information documents</p>	AR to contact department	For web	AR/SG	01/18
		<p><b>Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis, Uterine Fibroids (including pre-op use) or prior to Endometrial Ablation</b> Re format guideline for easier access to information. Treatment and duration to be advised by consultant.</p>	Re format wording as agreed.	Add to website	AR/SG	01/18
		<p><b>Clinical Guideline on the use of High-potency Vitamin D Replacement.</b> Updated document. To go to commissioners for comments and back to HERPC. Advice on pre-treatment vitamin D levels differs with Denosumab guideline. Consultants asked about it</p>	Noted	To come back to next HERPC	KM/AR	03/18
		<p><b>Guidelines for Treatment of Infections in Primary Care in Hull and East Riding</b> Changes of treatment for Chlamydia agreed. Move position of nitrofurantoin and trimethoprim in guideline for easier use.</p>	Noted	Upload on to website after amendments	AR/SG	01/18
		<p><b>Prescribing Framework for Modafinil for Daytime Hypersomnolence</b> Updated. Minor changes on the wording of responsibilities and indications were discussed and agreed.</p>	Noted	Upload on to website after amendments	AR/SG	01/18
		<p><b>Diabetes Mellitus - Traditional Diagnostic Criteria</b> – Updated document. Glucose tolerance test added.</p>	Noted	For web	AR/SG	01/18
		<p><b>Guideline on use of unlicensed medicines in primary care. Updated.</b> For review. Not discussed</p>	Noted	Deferred	AR/SG	01/18

2018.01.08	Correspondence Received	<b>Conditions for which over the counter items should not routinely be prescribed in primary care: A Consultation on guidance for CCGs.</b> Document to be sent to all parties providing services in Pharmacy care for comments. Questions rose about restricted conditions. Final document needed after consultation process	Circulate document	KM to circulate and ask for comments	KM	03/18
2018.01.09	Primary Care Rebate Scheme – Standing Item	None				
2018.01.10	Additional Minutes for Information	a)MMIG - November/December 17 (Confirmed) b)HEY D&T - November/December 17 (Confirmed) c)HFT DTC - December 17 (Draft) d)CHCP - none	Noted			01/18
2018.01.11	A.O.B.					
2018.01.12	Date and Time of Next Meeting	Wednesday 28th March 2018 1pm – 3pm, Board Room, Health House, Willerby, Hull				